Pages

Tuesday, August 26, 2014

After curing Cystic Fibrosis and Duchenne Muscular Dystrophy
with nonsense drug ataluren, PTC Therapeutics is moving on to relieving the sufferings of many more children afflicted with severe genetic diseases. This time it is spinal muscular atrophy (SMA). In a publication that recently appeared in SCIENCE, PTC Therapeutics has stumbled upon another orally bioavailable small molecule that is claimed to modulate an RNA processing event for therapeutic purposes.

The reason why I’m interested in the PTC story is that their small molecule approach to RNA modulation is counter-intuitive as it instinctively calls for a nucleic acid-based solution. On the other hand, an oral alternative to
what are usually more invasive routes of administration could have certain
advantages such as patient convenience and access.

In this example, the company began the panning process by hooking up RNA elements from the SMN2
gene that are involved in the splicing of an exon of interest with a luciferase reporter
gene so as to enable large-scale small molecule library screening. If left untouched, this reporter construct
will produce very little light emission due to luciferase expression. On the other hand, if the small molecule is successful
in biasing splicing towards the inclusion of exon 7, the intended outcome of this particular SMA treatment approach, then light is produced.

As one might expect there are numerous ‘hits’ that come out
of such primary screens. In this case, 2000
small molecules from the library increased luciferase expression. Since such expression changes can be due to a myriad of causes, selected candidates were put through a
number of tests such as whether the increase was dependent on the SMN2
sequence elements (reporter constructs without the SMN2 sequences would take
care of this), whether the selected small molecules change the expression or splicing of other RNAs (à off-targets; e.g. by
RNA seq) etc.

RG7800 apparently survived all these tests and was found to increase the desired SMN2 splice
form by about 70% in a number of cell models (including patient-derived cells)
and in a mouse model. It also has entered
clinical development.

Comparison with ISIS drug

Since RG7800 is in direct competition with antisense drug candidate ISIS-SMNRx by ISIS and Biogen as both aim to increase SMN2 exon inclusion, a brief comparison is warranted.

While RG7800 has the obvious advantage of being orally bioavailable versus the need for intrathecal administration of ISIS-SMNRx, in terms of molecular outcome, exon inclusion in spinal motor neurons, it appears to be lacking: a ~70% increase compared to ~100-150% increases in the
good SMN2 isoform achieved by ISIS-SMNRx in two clinical trials in SMA infants and children, and
even more than that in rodent studies before (Passini et al. 2011). However, RG7800
achieves SMN2 splice modulation not just in the motorneurons of the CNS, but in
many other places, in and outside the CNS.

There is ongoing debate as to whether such body-wide
modulation is required, a question also prompted by a study by ISIS and
collaborators on the systemic/subQ application of the antisense drug (Hua et al. 2011). Parenthetically, this also means that if ISIS/Biogen wanted global SMN2 regulation, they have an option with subcutaneous administration in addition to intrathecal administration. Interestingly, with the subcutaneous administration of ISIS-SMNRx, the mice lived much longer than
when the oligo was given intrathecally (days/weeks versus months).
Indeed, consistent with those studies, the PTC small molecule also
prolonged the lives of SMA mice considerably.

I guess it will have to be the clinical trials which will be most
informative as to whether this is an artefact of the mouse model or not. If so, systemic drug exposure would add no benefit and only increase the risk of adverse events from off-targeting.

At the end of the day, what I find remarkable is that it is apparently
possible to find small molecules that can modulate gene expression in a fairly sequence-selective manner. While I don’t doubt
that you can change splicing with small molecules, it is the apparent
specificity of a simple molecule such as RG7800 that perplexes me.

PTC Therapeutics did not disclose how many
compounds they had to sift through to find RG7800. If they really just picked one
or a few after the initial screen that yielded ~2000 hits and then got lucky, I’d be quite skeptical. Adding to my skepticism is that drug concentrations in the CNS were reported that greatly (>10x) exceeded those in the plasma (supplementary figure S7). I’m no small molecule guy, but for an
oligo guy who has been following drug development in general, that seems very
unique. The blood-brain-barrier apparently does not exist for PTC.

As a result, and also given the
controversy around the discovery of ataluren (artefact or not) and the fact
that PTC Therapeutics itself can only remotely speculate on the mechanism of
action of RG7800, I acknowledge the publication as interesting, but am not
ready to jump on board just yet.

3 comments:

Anonymous
said...

On Tekmira's last CC Mark Murray,when asked about progress on SubQ administration, answered oddly in saying they haven't closed out SubQ work, but Tekmira was focusing on "other" options for dosing patients. Do you think that Oral administration of Tekmira's products are possible? Thanks in advance for your consideration. @plilong

Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.